401 related articles for article (PubMed ID: 15013267)
1. The outpatient treatment of deep vein thrombosis delivers cost savings to patients and their families, compared to inpatient therapy.
Rodger MA; Gagné-Rodger C; Howley HE; Carrier M; Coyle D; Wells PS
Thromb Res; 2003; 112(1-2):13-8. PubMed ID: 15013267
[TBL] [Abstract][Full Text] [Related]
2. Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation.
Huse DM; Cummins G; Taylor DC; Russell MW
Am J Manag Care; 2002 Jan; 8(1 Suppl):S10-6. PubMed ID: 11822346
[TBL] [Abstract][Full Text] [Related]
3. Cost savings and effectiveness of outpatient treatment with low molecular weight heparin of deep vein thrombosis in a community hospital.
Lee M; Pao D; Hsu T; Sonderskov A
Can J Clin Pharmacol; 2004; 11(1):e17-27. PubMed ID: 15226523
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis.
Rodger M; Bredeson C; Wells PS; Beck J; Kearns B; Huebsch LB
CMAJ; 1998 Oct; 159(8):931-8. PubMed ID: 9834718
[TBL] [Abstract][Full Text] [Related]
5. Cost comparison of at-home treatment of deep venous thrombosis with low molecular weight heparin to inpatient treatment with unfractionated heparin.
Smith BJ; Weekley JS; Pilotto L; Howe T; Beven R
Intern Med J; 2002; 32(1-2):29-34. PubMed ID: 11783670
[TBL] [Abstract][Full Text] [Related]
6. An outpatient program to treat deep venous thrombosis with low-molecular-weight heparin.
Pearson SD; Blair R; Halpert A; Eddy E; Mckean S
Eff Clin Pract; 1999; 2(5):210-7. PubMed ID: 10623053
[TBL] [Abstract][Full Text] [Related]
7. Shifting from inpatient to outpatient treatment of deep vein thrombosis in a tertiary care center: a cost-minimization analysis.
Boucher M; Rodger M; Johnson JA; Tierney M
Pharmacotherapy; 2003 Mar; 23(3):301-9. PubMed ID: 12627927
[TBL] [Abstract][Full Text] [Related]
8. Patient outcomes and cost analysis associated with an outpatient deep venous thrombosis treatment program.
Groce JB
Pharmacotherapy; 1998; 18(6 Pt 3):175S-180S. PubMed ID: 9853912
[TBL] [Abstract][Full Text] [Related]
9. Low-molecular-weight heparin, bemiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice: the ESFERA Study.
Santamaría A; Juárez S; Reche A; Gómez-Outes A; Martínez-González J; Fontcuberta J;
Int J Clin Pract; 2006 May; 60(5):518-25. PubMed ID: 16700847
[TBL] [Abstract][Full Text] [Related]
10. Cut DVT (deep vein thrombosis) treatment costs with outpatient program for low-molecular-weight heparin.
Clin Resour Manag; 2000 Feb; 1(2):24-6, 17. PubMed ID: 11183279
[TBL] [Abstract][Full Text] [Related]
11. Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis--an economic evaluation. TASMAN Study Group.
van den Belt AG; Bossuyt PM; Prins MH; Gallus AS; Büller HR
Thromb Haemost; 1998 Feb; 79(2):259-63. PubMed ID: 9493572
[TBL] [Abstract][Full Text] [Related]
12. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
Holzheimer RG
Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
[TBL] [Abstract][Full Text] [Related]
13. Low-molecular weight heparin for deep vein thrombosis prophylaxis in hospitalized medical patients: results from a cost-effectiveness analysis.
Shorr AF; Jackson WL; Weiss BM; Moores LK
Blood Coagul Fibrinolysis; 2007 Jun; 18(4):309-16. PubMed ID: 17473570
[TBL] [Abstract][Full Text] [Related]
14. Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin.
Signorovitch JE; Sheng Duh M; Sengupta A; Gu A; Grant R; Raut M; Mody SH; Schein J; Fisher AC; Ng D
Curr Med Res Opin; 2010 Feb; 26(2):355-63. PubMed ID: 19995325
[TBL] [Abstract][Full Text] [Related]
15. Treatment of pulmonary embolism: The use of low-molecular-weight heparin in the inpatient and outpatient settings.
Hull RD
Thromb Haemost; 2008 Mar; 99(3):502-10. PubMed ID: 18327398
[TBL] [Abstract][Full Text] [Related]
16. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective.
Hull RD; Raskob GE; Rosenbloom D; Pineo GF; Lerner RG; Gafni A; Trowbridge AA; Elliott CG; Green D; Feinglass J
Arch Intern Med; 1997 Feb; 157(3):289-94. PubMed ID: 9040295
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of ambulatory and inpatient treatment of acute deep venous thrombosis of the leg: subjective and economic aspects].
Frank D; Blättler W
Schweiz Med Wochenschr; 1998 Sep; 128(36):1328-33. PubMed ID: 9784675
[TBL] [Abstract][Full Text] [Related]
18. Management of acute proximal deep vein thrombosis: pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparin.
Spyropoulos AC; Hurley JS; Ciesla GN; de Lissovoy G
Chest; 2002 Jul; 122(1):108-14. PubMed ID: 12114345
[TBL] [Abstract][Full Text] [Related]
19. Treatment of deep vein thrombosis using low-molecular-weight heparins.
Groce JB
Am J Manag Care; 2001 Nov; 7(17 Suppl):S510-5; discussion S515-23. PubMed ID: 11732662
[TBL] [Abstract][Full Text] [Related]
20. Comparative cost analysis of outpatient and inpatient rehabilitation for musculoskeletal diseases in Germany.
Zeidler J; Mittendorf T; Vahldiek G; Zeidler H; Merkesdal S
Rheumatology (Oxford); 2008 Oct; 47(10):1527-34. PubMed ID: 18682412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
